0-MSH, 373 Mucopeptide, 307
Mulberry dwarf disease, tetracyclines and, 299
Multisite mutations, 216
Mumps virus, amantadine and, 239 Murein, 307
Murine leukemia virus, streptovaricin and, 197
Murine RNA tumor viruses, 251
Muscle contraction-relaxation, effect of calcium and cardioactive steroids on, 12
Mutagenesis
base analog-induced, 226 proflavine-induced, 226
Mutants, detection and isolation of, 207-211
Mutator genes, 217 Mycobacteria, 247
streptolydigin and, 185
Mycobacterium tuberculosis, streptovari
cin and, 186 Mycophenolic acid, 340 Mycoplasma, 277-278, 298-301
etiology, 298 morphology of, 278 tetracyclines and, 298-301 Myxin, DNA replication and, 328 Myxovirus, replication of, 242
Ν
Na-dependent phosphorylation, 7 diisopropylfluorophosphate and, 31 Mg:ATP ratio and, 6
Mg-dependent conformational change during, 6
Na-dependent transphosphorylation, 5 N A D
ADH isozyme mobility and, 389-390 LDH isozymes zymogram pattern and,
390-391
NADH dehydrogenase, 320 NaK-ATPase, 2-38
acetone and, 34
acetyl phosphate, inhibition by, 6 alcohols, effect of, 34
amino acid transport and, 83 anesthetics, effect of, 34 arsenite, effect of, 22-23 beef brain, inhibition by Pi, 7 beryllium ions, effect of, 32 binding site affinity for ATP and
ADP, 7
Ca-ATP complex, inhibition by, 7 calcium chloride, effects of, 7-8 calf kidney, 24
cardiac muscle, 12
cardioactive glycosides and, 2 inhibition by, 8
cardioactive steroids and, 8-18 inhibition by, 8
time dependence, 15 cat and rat cerebral cortex, 13 catalysis of K+-dependent phosphatase
activity by, 13 cations, effect of, 5-6 cation transport and, 2-5
chlorinated hydrocarbons, effects of, 33
chlorpromazine, effect of, 25
chlorpromazine free radical, effect of, 25-26
choroid plexus, 20
competitive inhibition by IDP, GDP, and ADP, 6-7
complexes with cardioactive glycosides, 14
conformational changes, ligand in-duced, 38
crab nerve, inhibition by calcium, 7 CTP, GTP, and ITP as substrates,
6
detergents, effect of, 36-37
diethyl-p-nitrophenyl phosphate, effect of, 32
diethylstilbestrol, effect of, 36 diisopropylfluorophosphate, effect of,
31-32 distribution, 3
divalent ions, effect on, 7
dog kidney microsomal fractions, 15 electric organ, 7
Electrophorus, 23, 24 erythromycin, effect of, 28
Erythrophleum alkaloids and, 19-20 ethacrynic acid, effect of, 23-24 guinea pig kidney, 18
HeLa cells, 9
hexestrol, effect of, 36
human platelet, inhibition by, Pi, 7 iodoacetamide, effect of, 24-25 iodoacetate, effect of, 24-25 iodoacetate esters, effect of, 24-25 ITP, competitive inhibition by, 6 kidney cortex, 7
lamb brain, 18
leucine, stimulation by, 9
level, kidney surgical removal and, 3 maleimide derivatives, effect of, 21 methanesulfonyl chloride, effect of, 32 methymycin, effect of, 28
Mg:ATP optimal ratio, 5
Na+-dependent phosphorylation of, 7 Na:K, optimal ratio, 5
neurotropic agents, effects of, 33-35 oligomycin, effects of, 27-29 organic mercurials, effect of, 21 organic solvents, effect of, 34 ouabain
inhibition by, 8 effect of age on, 12
interaction with phosphorylated intermediate, 15
ouabain-sensitive sodium pump, 49 oxidation by performic acid, 17 oxophenarsine, effect of, 22-23 phenothiazines, effect of, 25 phloretin, effect of, 36 phlorizin, effect of, 36 phosphorylation of, 4 pig brain, 11
products, effect of, 6-7
proteolytic enzymes, effect of, 38 purgatives and, 37
rabbit kidney, 7 rutamycin, effect of, 28 in salt gland of herring gull, 3 specificity for ATP, 6
squid giant axon, 6 substrates, effect of, 6 sulfhydryl reagents and, 20-27 tetraethyl pyrophosphate, effect of, 32 toxicity of divalent ions, 35
turnover number, 17 urea, effect of, 37-38
Vibrio cholerae inhibitor and, 38 NaK-ATPase-cardiac glycoside
interac-tion
dose and time dependence, 14 influencing factors, 14-18 modification by ligands, 14 NaK-ATPase-ouabain complex
conformational potential of, 17 half-life of, 18
SUBJECT I N D E X 493
in vivo stability in dog cardiac muscle, 15
Nalidixic acid, 306
nap locus, amino acid transport and, 101 Napthomycin, 322
Natriuresis, ouabain and, 15 NDV, see Newcastle disease virus Necrotic ring spot viruses, 286 Negamycin, 336
Negative control systems, 137, 166 Jacob-Monod model and, 137 NEM, see iV-Ethylmaleimide Neocarzinostatin, DNA synthesis and,
194 Neomycin
miscoding and, 334-335 mycoplasmas and, 299
Neoplasia, gene derepression and, 159 Neplastic cells, RNA-dependent DNA
polymerase of, 197 Neoplastic transformation, 110 Nerve growth factor, 93 Neuraminidase
antiviral agents and, 241 isozyme production by, 397 Neurohypophyseal hormones, 362, 364 Neurological disorders, RNA viruses
and, 197
Neuromuscular disorders, 33 Neurosecretions, 361 Neurospora
operon system of, 155 polyoxin D and, 311 sugar transport in, 60-61 Neurospora crassa
osmotic shock in, 89
mutants, amino acid transport in, 101 Neurospora sitophila, 283
Neurotropic agents, effect on NaK-ATPase, 33-35
Neutral amino acid transport, 80 pH and, 88
Newcastle disease virus amantadine and, 239
cytoplasmic multiplication of, 252 NGF, 93
Nicotiana glutinosa, 281 Nicotiana tabacum, 280 Nicotinic acid biosynthesis, 342
Nigericin, 316-318, 343 Nitrate reductase, 209-210 Nitrobenzene, 59
F D N B inhibition and, 59 Nitrogen mustard, 225
immunosuppression and, 111 Nitrogen starvation, 92
o-Nitrophenyl-/3-D-fucoside (ONPF), DNA-/ac repressor binding and, 139 p-Nitrophenyl phosphate, 4
hydrolysis by NaK-ATPase, 6 o-Nitrophenylsulfenyl chloride, 376 Nitrostyrene derivatives, RNA virus
replication and, 257 Nitrous acid, 226
D N A interstrand cross-links and, 224 point mutants and, 224
Nitrous acid-induced mutants, 219 Nocardia asteroides, streptolydigin and,
185
Nogalamycin, 187-188, 325 DNA complex with, 176 Nonadapting amino acids, 98-99 Nonexchanging carrier (A system), 81 Nonhistone proteins, gene repression
and, 158
Nonhistone repressors, 158-159 Nonmetabolizable sugars, effect on
amino acid uptake, 91 Novikoff hepatoma cells, 253 Novobiocin
chelation of magnesium, 346 nucleic acid synthesis and, 196 wall synthesis and membrane
per-meability and, 328 NPS-ACTH, 376
Nuclear transplantation in Amoeba proteus, 164
Nucleases, 221-224
Nucleated erythrocytes, histones of, 157 Nucleic acid
biosynthesis, inhibitors, classification of, 175-176
replication, 176 Nucleocapsid antigen, 252
Nucleolar RNA synthesis, actinomycin D and, 177
Nucleoside antibiotics, 176 Nucleoside phosphorylase, 263
Nucleotide triphosphates, ouabain-NaK-ATPase binding and, 18
Nystatin, 65-66
Ο
Oleandomycin, mycoplasmas and, 299 Oligomycin, 322
erythrocyte membrane NaK-ATPase, effect on, 28
mitochondrial oxidative phosphoryla
tion and, 27-28 NaK-ATPase
effect on, 27-29 inhibition of, 63-64
ouabain-sensitive ATP hydrolysis and, 28
Olivomycin, 188, 326 DNA complex with, 176
0° Mutants, /3-galactosidase synthesis and, 138
Oncogenic RNA virions, 197 One gene-one repressor histone, 158 ONPF, 139
Operators, 136
Operon, Jacob-Monod model, 136-137 Operon 0L, 141
Operon OR, λ phage of, 141 Operon systems
of bacteria, 155, 165 differentiation and, 155 eukaryotes and, 155
Organ transplantation, 110, 126-128 survival percentage, 127-128 Organic mercurial diuretics, 20 Organic mercurials
NaK-ATPase, effect on, 21 Organic solvents, effect on membrane
lipids, 64 Orotic acid, 181 Oryza sativa, 280 Osmotic fragility, 307
Osmotic shock, amino acid transport and, 89
Osmotic work, 72 Ossamycin, 322 Ouabagenin, 10 Ouabain, 8, 9
amino acid transport and, 84, 87
induction of natriuresis, 15 Na-dependent ADP-ATP exchange
and, 14
NaK-ATPase, inhibition of, 63-64 NaK-ATPase phosphorylated inter
mediate and, 15
Ouabain-induced water uptake, 13 Ouabain-NaK-ATPase binding, 18 nucleotide triphosphates and, 18 Ouabain-NaK-ATPase complex
conformation potential of, 17 detergents, effect of, 37 half-life of, 18
Oviduct cells, gene derepression by hor
mones, 160
Oxalate, LDH isozymes and, 400 Oxaloacetate, heat inactivation of LDH
and, 413
Oxamate, LDH isozymes and, 400 Oxanilic acid, LDH isozymes and, 418 Oxidation of NaK-ATPase by performic
acid, 17
Oxidative phosphorylation, 313 2,4-dinitrophenol and, 29 inhibitors of, 62 oligomycin and, 27-28 valinomycin and, 314
Oxophenarsine, effect on NaK-ATPase, 22-23
Oxygen availability, amino acid trans
port and, 94
Oxytetracycline, mycoplasmas and, 298-299
Oxytocin
analogs, 372-373
structural rigidity of, 362
Ρ
Ρ proteins, 164-165 Pactamycin, 336 PAD, 35
Pancreatic amino acid transport, 97 Papain, 285
Paramyxoviruses, actinomycin D and, 251
Parathyroid gland, calcium and amino acid uptake in, 88